Morgan Stanley Starts Exscientia PLC (EXAI) at Equalweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
UPDATE: BofA Securities Starts Exscientia PLC (EXAI) at Buy on AI Enabled Drug Platform
October 26, 2021 6:07 AM EDT(Updated - October 27, 2021 7:27 AM EDT)
BofA Securities analyst Michael Ryskin initiates coverage on Exscientia PLC (NASDAQ: EXAI) with a Buy rating and a price target of $27.00.
The analyst stated "Exscientia is a tech-enabled drug discovery platform company, leveraging artificial... More



